유럽 ​​아달리무맙 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

유럽 ​​아달리무맙 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • May 2022
  • Europe
  • 350 Pages
  • 테이블 수: 218
  • 그림 수: 54

>유럽 ​​아달리무맙 시장, 적응증( 류마티스 관절염 , 소아 특발성 관절염, 건선성 관절염, 강직성 척추염, 크론병, 농양성 히드라데니티스, 궤양성 대장염, 만성 플라그 건선, 비감염성 중간체 및 기타), 유형(생물학적 제제 및 바이오시밀러), 용량 강도(20MG/0.4MLG, 40MG/0.8MLG 및 기타), 약물 유형(휴미라, 암제비타, 임랄디, 하이리모즈, 유플리마, 훌리오, 이다시오), 인구 유형(어린이 및 성인), 최종 사용자(병원, 전문 클리닉, 재택 건강 관리 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타) 산업 동향 및 2029년까지의 예측.

유럽 ​​아달리무맙 시장

시장 정의

아달리무맙은 류마티스 관절염, 크론병 등을 포함한 특정 자가면역 질환을 치료하는 데 사용되는 단일클론 항체 중 하나입니다. 아달리무맙은 염증 증상 치료에 사용되는 항-TNF 약물입니다. 아달리무맙의 생물학적 제제는 휴미라이며, 휴미라의 다양한 바이오시밀러 약물도 이용 가능하며, 여기에는 Exemptia, Hyrimoz, Cyltezo, Hulio 등이 포함됩니다. 아달리무맙은 TNF 인자 알파에 결합하여 작용하여 자가면역 질환에 대한 염증 반응의 가능성을 줄입니다.

시장 분석 및 통찰력

유럽 ​​아달리무맙 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 16.2%의 CAGR로 성장하고 있으며 2021년 3,485.94백만 달러에서 2029년까지 10,337.79백만 달러에 도달할 것으로 분석합니다.

유럽 ​​아달리무맙 시장

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020

양적 단위

수익 (단위: USD 백만)

다루는 세그먼트

적응증(류마티스 관절염, 소아 특발성 관절염, 건선성 관절염, 강직성 척추염, 크론병 , 농양성 히드라데니티스, 궤양성 대장염, 만성 플라그 건선, 비감염성 중간체 및 기타), 유형(생물학적 제제 및 바이오시밀러) , 용량 강도(20MG/0.4MLG, 40MG/0.8MLG 및 기타), 약물 유형(휴미라, 암제비타, 임랄디, 하이리모즈, 유플리마, 훌리오, 이다시오), 인구 유형(어린이 및 성인), 최종 사용자(병원, 전문 병원, 가정 의료 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타)

적용 국가

독일, 프랑스, ​​이탈리아, 영국, 스페인, 네덜란드, 러시아, 스위스, 벨기에, 터키, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드 및 기타 유럽

시장 참여자 포함

시장에서 거래하는 주요 회사로는 AbbVie Inc., Sandoz International GmbH, Amgen Inc., Mylan NV(Viatris의 자회사), Biogen, Celltrion Healthcare Co., Ltd., Fresenius Kabi SwissBioSim GmbH, Alvotech, Biocad, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Synermore Biologics, Prestige BioPharma Ltd., Janssen Global Services, LLC 등이 있습니다.

Adalimumab Market Dynamics

Drivers

  • Increasing prevalence of rheumatoid arthritis

The prevalence of rheumatoid arthritis is increasing worldwide and this has been reported that globally, the annual incidence of RA is nearly 3 cases per 10,000 populations. Rheumatoid arthritis leads to development of inflammatory symptoms which can be treated by several drug therapies involving biological therapies among others. One of the most innovative biological therapy discovered for treatment of rheumatoid arthritis includes adalimumab, a monoclonal antibody which targets the immune cells and slows down the recruitment of immune cells that leads to decrease the inflammation at target site. The continuous rise in rheumatoid arthritis globally and in the European region has badly affected the life of sufferers and thus disease is also putting a great burden over the healthcare professionals.

  • Rise in geriatric population

The geriatric population is increasing living for longer period of time with several types of chronic conditions. This has been reported that the pace of ageing population is too high and is expanding at a dramatic rate. The condition of rheumatoid arthritis is said to be associated with increase in older population. According to a study, about 703 million people were over the age of 65 years old or over in the year 2019. North America and Europe had over 200 million older age people. The study also suggested that the population has already been observed to be significantly older and rising slowly about 48%. Adult’s population suffering from rheumatoid arthritis is increasing who are largely dependent on adalimumab therapy. This thus signifies that increasing geriatric population is acting as driver for market growth.

  • Increasing number of contract research organizations (CRO)

Contract research organizations provide with the support for clinical trials and other research activities conducted for drugs and medical devices. Contract Research Organisation (CRO) helps biotechnology and pharmaceutical industries for the drug development process and to reduce the overall cost of clinical trials. As various adalimumab are extensively under the clinical trials in order to fulfil the unmet demands of patients suffering from inflammatory diseases, the increasing number of contract research organizations is boosting the market growth. There is an increase in the number of contract research organizations which has simplified the process of adalimumab drugs and reduced the time needed for drug development.

유럽 ​​아달리무맙 시장

Opportunities

  • Strategic initiatives by market players

The demand for adalimumab has boosted in the region as well as globally, due to the growth in the rise in various chronic diseases and the rise in geriatric population. These favourable factors accomplishing enhance the need for the drugs, and to accomplish the market demand, minor and major market players are utilizing various strategies

Also, the rise in healthcare expenditure by the government in the region will provide structural integrity and future opportunities for the adalimumab market in the forecast period of 2022-2029.

Restraints/Challenges

However, the high cost associated with the drugs and some side effects seen after using drugs may hamper the growth of the market. Additionally, stringent rules and regulations will further challenge the market in the forecast period mentioned above.

This adalimumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on arthritis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post COVID-19 Impact on Adalimumab Market

The COVID-19 has not that much affected in the growth of the market. As there is rise in the prevalence of various diseases in the region such as rheumatoid arthritis, Crohn’s diseases and among others lead to rise in the development of various drugs in the market. Hence the need for the adalimumab drugs keep rising in the COVID-19 period as well.

Recent Development

  • In October 2018, Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, HyrimozTM (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC) and plaque psoriasis (Ps).

Europe Adalimumab Market Scope

Europe adalimumab market is segmented into indication, type, dosage strength, drug type, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Indication

  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Hidradenitis Suppurativa
  • Ulcerative Colitis
  • Chronic Plaque Psoriasis
  • Non-Infectious Intermediate
  • Others

유럽 ​​아달리무맙 시장은 적응증을 기준으로 류마티스 관절염, 소아 특발성 관절염, 건선성 관절염, 강직성 척추염, 크론병, 농양성 히드라데니티스, 궤양성 대장염, 만성 플라그 건선, 비감염성 중간형 건선 및 기타로 구분됩니다.

유형

유럽 ​​아달리무맙 시장은 유형을 기준으로 생물학적 제제와 바이오시밀러로 구분됩니다.

복용량 강도

  • 20MG/0.4MLG
  • 40MG/0.8MLG
  • 기타

유럽 ​​아달리무맙 시장은 용량 강도에 따라 20MG/0.4MLG, 40MG/0.8MLG 및 기타로 구분됩니다.

약물 유형

  • 휴미라
  • 암제비타
  • 임랄디
  •  하이리모즈
  •  유플리마
  •  훌리오
  •  이다시오

약물 유형을 기준으로 유럽 아달리무맙 시장은 휴미라(Humira), 암제비타(Amgevita), 임랄디(Imraldi), 하이리모즈(Hyrimoz), 유플라이마(Yuflyma), 훌리오(Hulio) 및 아이다시오(Idacio)로 분류됩니다.

인구 유형

  • 어린이들
  • 성인

인구 유형을 기준으로 유럽 아달리무맙 시장은 어린이와 성인으로 구분됩니다.

최종 사용자

  • 병원
  • 전문 클리닉
  • 홈 헬스케어
  • 기타

최종 사용자를 기준으로 유럽 아달리무맙 시장은 병원, 전문 진료소, 가정 건강 관리 및 기타로 구분됩니다.

유통 채널

  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 기타

유럽 ​​아달리무맙 시장

유럽 ​​아달리무맙 시장은 유통 채널을 기준으로 병원 약국, 소매 약국, 온라인 약국 및 기타로 구분됩니다.

아달리무맙 시장 지역 분석/통찰력                   

위에 언급된 대로, 아달리무맙 시장을 분석하고, 국가, 적응증, 유형, 복용량 강도, 약물 유형, 인구 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

유럽 ​​아달리무맙 시장은 독일, 프랑스, ​​이탈리아, 영국, 스페인, 네덜란드, 러시아, 스위스, 벨기에, 터키, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드 및 기타 유럽 국가로 세분화됩니다.

독일은 시장 점유율과 시장 수익 측면에서 아달리무맙 시장을 지배하고 있으며 예측 기간 동안 지배력을 계속 확대할 것입니다. 이는 다양한 만성 질환의 유병률 증가와 독일 지역의 약물 개발 연구 개발로 인해 이 시장 성장이 더욱 개선되기 때문입니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규정의 변화를 제공합니다. 신규 및 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 국내 및 국내 브랜드와의 치열한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 시장 점유율 분석

아달리무맙 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 회사의 아달리무맙 시장에 대한 초점과만 관련이 있습니다.

아달리무맙 시장에서 활동하는 주요 기업으로는 AbbVie Inc., Sandoz International GmbH, Amgen Inc., Mylan NV(Viatris의 자회사), Biogen, Celltrion Healthcare Co., Ltd., Fresenius Kabi SwissBioSim GmbH, Alvotech, Biocad, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Synermore Biologics, Prestige BioPharma Ltd., Janssen Global Services, LLC 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 유럽 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 것을 자랑으로 생각합니다. 보고서는 타겟 브랜드의 가격 추세 분석, 추가 국가 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 타겟 경쟁업체의 시장 분석은 기술 기반 분석에서 시장 포트폴리오 전략까지 분석할 수 있습니다. 필요한 만큼 많은 경쟁업체를 원하는 형식과 데이터 스타일로 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 Excel 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용할 수 있는 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE ADALIMUMAB MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 INDICATION LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 PIPELINE ANALYSIS

4 REGULATORY FRAMEWORK OF EUROPE ADALIMUMAB MARKET

5 EPIDEMIOLOGY

6 ADALIMUMAB PRESCRIPTION

7 EUROPE ADALIMUMAB MARKET: REIMBURSEMENT SCENARIO

7.1 REIMBURSEMENT SCENARIO IN THE U.S.

7.2 REIMBURSEMENT SCENARIO IN CHINA

7.3 REIMBURSEMENT SCENARIO IN JAPAN

7.4 REIMBURSEMENT IN CENTRAL AND EASTERN EUROPE

7.5 REIMBURSEMENT SCENARIO IN DENMARK

7.6 REIMBURSEMENT SCENARIO IN IRELAND

8 IMPACT OF BIOSIMILAR

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISE IN THE PREVALENCE OF RHEUMATOID ARHTRITIS

9.1.2 INCREASING GERIATRIC POPULATION

9.1.3 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS

9.1.4 INTRODUCTION TO BIOSIMILARS

9.1.5 EXPLORATION OF EMERGING MARKETS

9.2 RESTRAINTS

9.2.1 HIGH COSTS OF DRUGS

9.2.2 SIDE EFFECTS OF DRUGS

9.2.3 CANCER CAUSING DRUGS

9.3 OPPORTUNITIES

9.3.1 PRESENCE OF PRODUCT PIPELINE

9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

9.3.3 INCREASING HEALTHCARE EXPENDITURE

9.3.4 PRESENCE OF REIMBURSEMENT POLICIES

9.4 CHALLENGES

9.4.1 LOSS OF PATENTS

9.4.2 AVAILABILITY OF ALTERNATIVES

9.4.3 LONG APPROVAL PROCEDURE

10 COVID-19 IMPACT ON ADALIMUMAB IN HEALTHCARE INDUSTRY

10.1 OVERVIEW

10.2 ADALIMUMAB AND COVID-19

10.3 PRICE IMPACT OF COVID-19

10.4 IMPACT ON DEMAND

10.5 IMPACT ON SUPPLY CHAIN

10.6 STRATEGIC DECISIONS FOR MANUFACTURERS

10.7 CONCLUSION

11 EUROPE ADALIMUMAB MARKET, BY INDICATION

11.1 OVERVIEW

11.2 RHEUMATOID ARTHRITIS

11.3 ANKYLOSING SPONDYLITIS

11.4 CHRONIC PLAQUE PSORIASIS

11.5 CROHN’S DISEASE

11.6 ULCERATIVE COLITIS

11.7 PSORIATIC ARTHRITIS

11.8 JUVENILE IDIOPATHIC ARTHRITIS

11.9 HIDRADENITIS SUPPURATIVA

11.1 NON-INFECTIOUS INTERMEDIATE

11.11 OTHERS

12 EUROPE ADALIMUMAB MARKET, BY TYPE

12.1 OVERVIEW

12.2 BIOLOGICS

12.3 BIOSIMILARS

12.3.1 ADALIMUMAB-ATTO

12.3.2 ADALIMUMAB-BWWD

12.3.3 ADALIMUMAB-ADBM

12.3.4 ADALIMUMAB-ADAZ

12.3.5 ADALIMUMAB-FKJP

12.3.6 ADALIMUMAB-AFZB

12.3.7 OTHERS

13 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH

13.1 OVERVIEW

13.2MG/0.4ML

13.3MG/0.8ML

13.4MG/0.4ML

13.5MG/0.1ML

13.6 OTHERS

14 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE

14.1 OVERVIEW

14.2 BRANDED

14.3 GENERICS

14.3.1 AMJEVITA

14.3.2 HYRIMOZ

14.3.3 HULIO

14.3.4 OTHERS

15 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION

15.1 OVERVIEW

15.2 PARENTERAL

15.3 ORAL

16 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE

16.1 OVERVIEW

16.2 ADULTS

16.3 CHILDREN

17 EUROPE ADALIMUMAB MARKET, BY END USER

17.1 OVERVIEW

17.2 HOSPITALS

17.3 SPECIALTY CLINICS

17.4 HOME HEALTHCARE

17.5 OTHERS

18 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL

18.1 OVERVIEW

18.2 HOSPITAL PHARMACIES

18.3 RETAIL PHARMACIES

18.4 ONLINE PHARMACIES

18.5 DIRECT TENDER

18.6 OTHERS

19 EUROPE ADALIMUMAB MARKET, BY GEOGRAPHY

19.1 EUROPE

19.1.1 GERMANY

19.1.2 U.K

19.1.3 ITALY

19.1.4 FRANCE

19.1.5 SPAIN

19.1.6 NETHERLANDS

19.1.7 RUSSIA

19.1.8 SWITZERLAND

19.1.9 BELGIUM

19.1.10 TURKEY

19.1.11 AUSTRIA

19.1.12 NORWAY

19.1.13 HUNGARY

19.1.14 LITHUANIA

19.1.15 IRELAND

19.1.16 POLAND

19.1.17 REST OF EUROPE

20 EUROPE ADALIMUMAB MARKET: COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: EUROPE

21 SWOT

22 COMPANY PROFILES

22.1 ABBVIE INC.

22.1.1 COMPANY SNAPSHOT

22.1.2 REVENUE ANALYSIS

22.1.3 COMPANY SHARE ANALYSIS

22.1.4 PRODUCT PORTFOLIO

22.1.5 RECENT DEVELOPMENTS

22.2 AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.)

22.2.1 COMPANY SNAPSHOT

22.2.2 REVENUE ANALYSIS

22.2.3 COMPANY SHARE ANALYSIS

22.2.4 PRODUCT PORTFOLIO

22.2.5 RECENT DEVELOPMENTS

22.3 BIOGEN

22.3.1 COMPANY SNAPSHOT

22.3.2 REVENUE ANALYSIS

22.3.3 PRODUCT PORTFOLIO

22.3.4 RECENT DEVELOPMENTS

22.4 SANDOZ INTERNATIONAL GMBH {A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG)}

22.4.1 COMPANY SNAPSHOT

22.4.2 REVENUE ANALYSIS

22.4.3 PRODUCT PORTFOLIO

22.4.4 RECENT DEVELOPMENTS

22.5 MYLAN N.V.

22.5.1 COMPANY SNAPSHOT

22.5.2 REVENUE ANALYSIS

22.5.3 PRODUCT PORTFOLIO

22.5.4 RECENT DEVELOPMENTS

22.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

22.6.1 COMPANY SNAPSHOT

22.6.2 REVENUE ANALYSIS

22.6.3 PRODUCT PORTFOLIO

22.6.4 RECENT DEVELOPMENTS

22.7 CELLTRION INC.

22.7.1 COMPANY SNAPSHOT

22.7.2 REVENUE ANALYSIS

22.7.3 PRODUCT PORTFOLIO

22.7.4 RECENT DEVELOPMENTS

22.8 COHERUS BIOSCIENCES

22.8.1 COMPANY SNAPSHOT

22.8.2 PRODUCT PORTFOLIO

22.8.3 RECENT DEVELOPMENTS

22.9 FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG)

22.9.1 COMPANY SNAPSHOT

22.9.2 REVENUE ANALYSIS

22.9.3 PRODUCT PORTFOLIO

22.9.4 RECENT DEVELOPMENTS

22.1 HETERO BIOPHARMA LTD.

22.10.1 COMPANY SNAPSHOT

22.10.2 PRODUCT PORTFOLIO

22.10.3 RECENT DEVELOPMENTS

22.11 INNOVENT BIOLOGICS, INC.

22.11.1 COMPANY SNAPSHOT

22.11.2 REVENUE ANALYSIS

22.11.3 PRODUCT PORTFOLIO

22.11.4 RECENT DEVELOPMENTS

22.12 PFIZER INC.

22.12.1 COMPANY SNAPSHOT

22.12.2 REVENUE ANALYSIS

22.12.3 PRODUCT PORTFOLIO

22.12.4 RECENT DEVELOPMENTS

22.13 RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED)

22.13.1 COMPANY SNAPSHOT

22.13.2 REVENUE ANALYSIS

22.13.3 PRODUCT PORTFOLIO

22.13.4 RECENT DEVELOPMENTS

22.14 SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS)

22.14.1 COMPANY SNAPSHOT

22.14.2 REVENUE ANALYSIS

22.14.3 PRODUCT PORTFOLIO

22.14.4 RECENT DEVELOPMENTS

22.15 ZYDUS CADILA

22.15.1 COMPANY SNAPSHOT

22.15.2 REVENUE ANALYSIS

22.15.3 PRODUCT PORTFOLIO

22.15.4 RECENT DEVELOPMENT

23 QUESTIONNAIRE

24 RELATED REPORTS

표 목록

LIST OF TABLES

TABLE 1 EUROPE ADALIMUMAB MARKET, PIPELINE ANALYSIS

TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.

TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)

TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS

TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT

TABLE 6 EUROPE ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)

TABLE 7 EUROPE RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 EUROPE ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 EUROPE CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 EUROPE CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 EUROPE ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 EUROPE PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 EUROPE JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 14 EUROPE HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 EUROPE NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 EUROPE ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 18 EUROPE BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 19 EUROPE BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 20 EUROPE BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 21 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)

TABLE 22 EUROPE 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 EUROPE 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 EUROPE 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 EUROPE 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 28 EUROPE BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 EUROPE GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 EUROPE GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 31 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)

TABLE 32 EUROPE PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)

TABLE 34 EUROPE ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 EUROPE CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 EUROPE ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 37 EUROPE HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 EUROPE SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 EUROPE HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 42 EUROPE HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 EUROPE RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 EUROPE ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 EUROPE DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 46 EUROPE OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 EUROPE ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 48 EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 49 EUROPE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 EUROPE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 52 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 53 EUROPE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 54 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 55 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 56 EUROPE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 57 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 GERMANYADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 59 GERMANYADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 60 GERMANYBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 GERMANYADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 62 GERMANYADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 63 GERMANY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 64 GERMANYADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 GERMANYADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 66 GERMANYADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 67 GERMANYADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 68 U.K ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 69 U.K ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 U.K BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 U.K ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 72 U.K ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 73 U.K GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 74 U.K ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 75 U.K ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 76 U.K ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 77 U.K ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 78 ITALY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 79 ITALY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 ITALY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 ITALY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 82 ITALY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 83 ITALY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 84 ITALY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 85 ITALY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 86 ITALY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 87 ITALY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 88 FRANCE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 89 FRANCE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 FRANCE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 FRANCE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 92 FRANCE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 93 FRANCE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 94 FRANCE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 95 FRANCE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 96 FRANCE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 97 FRANCE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 98 SPAIN ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 99 SPAIN ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 SPAIN BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 SPAIN ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 102 SPAIN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 103 SPAIN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 104 SPAIN ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 105 SPAIN ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 106 SPAIN ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 107 SPAIN ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 108 NETHERLANDS ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 109 NETHERLANDS ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 110 NETHERLANDS BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 NETHERLANDS ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 112 NETHERLANDS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 113 NETHERLANDS GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 114 NETHERLANDS ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 115 NETHERLANDS ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 116 NETHERLANDS ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 117 NETHERLANDS ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 118 RUSSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 119 RUSSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 120 RUSSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 121 RUSSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 122 RUSSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 123 RUSSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 124 RUSSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 125 RUSSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 126 RUSSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 127 RUSSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 128 SWITZERLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 129 SWITZERLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 130 SWITZERLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 131 SWITZERLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 132 SWITZERLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 133 SWITZERLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 134 SWITZERLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 135 SWITZERLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 136 SWITZERLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 137 SWITZERLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 138 BELGIUM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 139 BELGIUM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 140 BELGIUM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 141 BELGIUM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 142 BELGIUM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 143 BELGIUM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 144 BELGIUM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 145 BELGIUM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 146 BELGIUM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 147 BELGIUM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 148 TURKEY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 149 TURKEY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 150 TURKEY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 151 TURKEY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 152 TURKEY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 153 TURKEY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 154 TURKEY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 155 TURKEY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 156 TURKEY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 157 TURKEY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 158 AUSTRIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 159 AUSTRIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 160 AUSTRIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 161 AUSTRIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 162 AUSTRIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 163 AUSTRIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 164 AUSTRIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 AUSTRIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 166 AUSTRIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 167 AUSTRIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 168 NORWAY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 169 NORWAY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 170 NORWAY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 171 NORWAY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 172 NORWAY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 173 NORWAY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 174 NORWAY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 175 NORWAY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 176 NORWAY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 177 NORWAY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 178 HUNGARY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 179 HUNGARY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 180 HUNGARY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 181 HUNGARY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 182 HUNGARY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 183 HUNGARY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 184 HUNGARY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 185 HUNGARY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 186 HUNGARY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 187 HUNGARY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 188 LITHUANIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 189 LITHUANIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 190 LITHUANIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 191 LITHUANIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 192 LITHUANIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 193 LITHUANIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 194 LITHUANIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 195 LITHUANIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 196 LITHUANIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 197 LITHUANIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 198 IRELAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 199 IRELAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 200 IRELAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 201 IRELAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 202 IRELAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 203 IRELAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 204 IRELAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 205 IRELAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 206 IRELAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 207 IRELAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 208 POLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 209 POLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 210 POLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 211 POLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 212 POLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 213 POLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 214 POLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 215 POLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 216 POLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 217 POLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 218 REST OF EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

그림 목록

LIST OF FIGURES

FIGURE 1 EUROPE ADALIMUMAB MARKET: SEGMENTATION

FIGURE 2 EUROPE ADALIMUMAB MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE ADALIMUMAB MARKET: DROC ANALYSIS

FIGURE 4 EUROPE ADALIMUMAB MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE ADALIMUMAB MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE ADALIMUMAB MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE ADALIMUMAB MARKET: SEGMENTATION

FIGURE 11 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE EUROPE ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 12 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ADALIMUMAB MARKET IN 2020 & 2027

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE ADALIMUMAB MARKET

FIGURE 14 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)

FIGURE 15 FUNCTION OF CRO

FIGURE 16 HEALTHCARE EXPENDITURE IN 2016 AND 2019

FIGURE 17 EUROPE ADALIMUMAB MARKET: BY INDICATION, 2019

FIGURE 18 EUROPE ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION)

FIGURE 19 EUROPE ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027)

FIGURE 20 EUROPE ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 21 EUROPE ADALIMUMAB MARKET: BY TYPE, 2019

FIGURE 22 EUROPE ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION)

FIGURE 23 EUROPE ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 24 EUROPE ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2019

FIGURE 26 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH 2019-2027 (USD MILLION)

FIGURE 27 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2020-2027)

FIGURE 28 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE

FIGURE 29 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE, 2019

FIGURE 30 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE , 2019-2027 (USD MILLION)

FIGURE 31 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2020-2027)

FIGURE 32 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 33 EUROPE ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 34 EUROPE ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

FIGURE 35 EUROPE ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 36 EUROPE ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 37 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, 2019

FIGURE 38 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, 2019-2027 (USD MILLION)

FIGURE 39 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2020-2027)

FIGURE 40 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 41 EUROPE ADALIMUMAB MARKET: BY END USER, 2019

FIGURE 42 EUROPE ADALIMUMAB MARKET: BY END USER, 2019-2027 (USD MILLION)

FIGURE 43 EUROPE ADALIMUMAB MARKET: BY END USER, CAGR (2020-2027)

FIGURE 44 EUROPE ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE

FIGURE 45 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 46 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 47 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 48 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 49 EUROPE ADALIMUMAB MARKET: SNAPSHOT (2019)

FIGURE 50 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019)

FIGURE 51 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)

FIGURE 52 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)

FIGURE 53 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)

FIGURE 54 EUROPE ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Europe Adalimumab Market will be worth USD 10,337.79 million in the forecast period by 2029.
The Europe Adalimumab Market growth rate is 16.2% during the forecast period.
Increasing prevalence of rheumatoid arthritis, Rise in geriatric population and Increasing number of contract research organizations (CRO) are the growth drivers of the Europe Adalimumab Market.
Indication, type, dosage strength, drug type, population type, end user and distribution channel are the factors on which the Europe Adalimumab Market research is based.
Major companies in the Europe Adalimumab Market are AbbVie Inc. Sandoz International GmbH, Amgen Inc., Mylan N.V. (A subsidiary of Viatris), Biogen, Celltrion Healthcare Co., Ltd., Fresenius Kabi SwissBioSim GmbH, Alvotech, Biocad, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Synermore Biologics, Prestige BioPharma Ltd., and Janssen Global Services etc.